Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Medix Biochemica Launches MedixMAB by Design™ at AACC 2013

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
Highest quality recombinant antibody production service to ensure superior IVD tests.

Medix Biochemica announces the launch of its MedixMAB by Design™ antibody production service, at the annual AACC meeting in Houston, USA, 28 July – 1 August, 2013 (Booth 3606). Offering a completely customised service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design presents an excellent foundation for superior IVD assays. With antibodies produced to the strictest international quality standards, the new service equips IVD manufacturers with a competitive advantage, helping to increase sales revenue without the need to invest in costly production facilities and expertise.

The advanced production technology of the MedixMAB by Design service allows for the targeting of a broader range of antigens than possible in vivo, including poorly immunoreactive and toxic compounds, and recombinant MAB production is possible on a range of scales (mg-kg). As an alternative to producing full length MABs, Fab fragments can instead be generated in just three months, to greatly enhance specificity and sensitivity of an IVD assay in solid-phase applications. In addition to producing novel antibodies, existing antibodies can also be optimised, for example by humanisation, biotinylation or affinity maturation, for enhanced IVD test performance. Flexibility is an inherent feature of the MedixMAB by Design service, and a personal project manager provides full consultation and support throughout the process, tailoring the service to each individual need.

With the MedixMAB by Design service, high affinity recombinant antibodies exhibiting low cross-reactivity are produced using an advanced in vitro system, which incorporates the latest in cutting-edge phage display antibody production technology. To ensure the highest quality, the entire process is comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and FDA QSR quality standards. Furthermore, the in vitro production system yields a consistent level of quality between batches.

Product manager for MedixMAB by Design, Maija Partanen, commented: “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Skin patch to treat peanut allergy shows benefit in children
NIH-funded study suggests patch is safe, convenient mode of treatment.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos